Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05851599
Other study ID # CRSU-P-1-1019
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 12, 2020
Est. completion date August 8, 2021

Study information

Verified date May 2023
Source Medika Natura Sdn Bhd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study has been designed as a randomized, double blinded, multi-centric, placebo controlled and phase II dose-ranging study. One group will receive placebo alone and the other three groups will receive IP twice daily (different dosages) for four months.


Description:

Labisia pumila or Kacip Fatimah, a native Malaysian plant, has been used as traditional medicine for over 400 years by both men and women for multiple treatments. Studies in animal models showed that Labisia pumila extract could regulate body weight gain and visceral fat reduction. SKF7® is a standardized extract of Labisia pumila (Kacip Fatimah) from the Myrsinaceae family.


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date August 8, 2021
Est. primary completion date August 8, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Men aged 18 - 60 years. 2. Women aged 18 until before menopause. 3. BMI 30 - 37 kg/m2. 4. Waist circumference = 60% of height. 5. Generally healthy or in the presence of co-morbidities of treated or untreated hypertension, diabetes or hyperlipidaemia. 6. Normotension or well-controlled mild hypertension (< 140/90 mmHg) with stable dosage of not more than 2 class drug combination (except beta blocker and diuretic) for at least 1 month. 7. Normoglycemic or non-insulin dependent diabetes mellitus (HbA1c = 8.5%) with stable dosage of not more than 2 class drug combination (except sulphonylureas, TZDs and SGLT2 inhibitors) for at least 1 month. 8. Normolipidaemia or hyperlipidaemia (LDL = 4.1 mmol/L and TG = 5.6 mmol/L) with stable dosage of not more than 2 class drug combination for at least 1 month. 9. Agreed to maintain their current lifestyles (no changes in their diet and physical exercise) during the clinical trial period. 10. Willing to participate in the study by signing the informed consent. 11. Ability to provide written informed consent. Exclusion Criteria: 1. Known hypersensitivity to any herbal product. 2. Known history of allergic reaction to microcrystalline cellulose, maltodextrin, tricalcium phosphate, silicon dioxide and glyceryl monostearate. 3. Pregnant or lactating women. 4. Taking any other weight loss therapy or who have lost more than 10% of their body weight within the last 6 months. 5. Taking regular herbal drugs or any supplements unless subjects willing to stop during the study. 6. Known HIV subjects. 7. Severe liver function impairment (ALT & AST > 3x ULN (upper limit of normal) 8. Renal function impairment (serum creatinine > 132.6 µmol/L) 9. Participating in other interventional clinical study or have taken other investigational drug within 30 days prior to screening. 10. Having endocrine disease that may affect weight such as hypothyroidism or Cushing's syndrome (by anamnesis). 11. Taking hormonal contraceptive within the last 3 months or planning to use it during the study. 12. Female patient of childbearing potential who is planning to get pregnant/male patient who is planning to have a child or do not agree to use non-hormonal contraception for the entire duration of the study. 13. Having heart diseases (e.g. heart failure, angina pectoris, or myocardial infarction), respiratory diseases (e.g. asthma or obstructive pulmonary disease), stroke, or ischemic heart failure. 14. Having malignant tumors within the last 5 years. 15. Participants who have narrow-angle glaucoma. 16. Participants who have cholelithiasis. 17. Participants with a neurologically or psychologically significant history of disease or who are currently suffering from the disease (e.g. schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, hyperphagia, etc.). 18. Participants who have taken oral steroids (e.g. prednisone or its equivalent) within the last 3 months that may affect weight. 19. Participants who have taken b-blocker or diuretic drugs for hypertension, anorexiants, laxatives, thyroid hormone, amphetamine, cyproheptadine, phenothiazine, contraceptive or female hormones within the last 3 months that may affect weight. 20. Participants who have taken other treatments (e.g. insulin, blood thinning, antidepressants, selective serotonin reuptake inhibitors (SSRIs), barbiturate, antipsychotics, antiepileptic, or drugs concerned with abuse) within the last 5 years. 21. Participants who have anatomical condition or underwent anatomical changes which make it difficult/unable to conduct physical measurements. 22. Participants who underwent surgeries for weight reduction (e.g., gastroplasty or gastrectomy). 23. Participants who are judged as unable to comply with the study according to the findings of the clinical investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
SKF7® Labisia pumila standardized extract
Botanical extract of Labisia pumila (Kacip Fatimah)

Locations

Country Name City State
Malaysia Klinik Kesihatan Greentown Ipoh
Malaysia Klinik Kesihatan Kuang Kuang
Malaysia Hospital Melaka Melaka
Malaysia Klinik Kesihatan Masjid Tanah Melaka
Malaysia Hospital Tuanku Jaafar Seremban
Malaysia Klinik Kesihatan Seremban 2 Seremban

Sponsors (2)

Lead Sponsor Collaborator
Medika Natura Sdn Bhd Zach Biotech Depot Sdn Bhd

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients achieving more than or equal to 5% weight loss OR Percentage of patients achieving more than or equal to 5% weight loss for SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Primary Percentage of patients achieving more than or equal to 5 cm waist circumference reduction Percentage of patients achieving more than or equal to 5 cm waist circumference reduction for SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Secondary Percentage change from baseline in body weight (kg) at week 16 SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Secondary Percentage change from baseline in waist circumference (cm) at week 16 SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Secondary Percentage change from baseline in waist to height ratio at week 16 SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Secondary Percentage change from baseline in BMI at week 16 SKF7® (375 mg, 562.5 mg and 750 mg) versus placebo Baseline Day 1 to Week 16
Secondary Change in blood lipid concentrations. The change in blood lipid concentrations (total cholesterol, triglyceride, HDL & LDL) Baseline Day 1 to Week 16
Secondary Incidence of AEs, SAEs and AEs leading to early discontinuation Incidence of AEs, SAEs and AEs leading to early discontinuation Up to Follow up visit Up to Week 17
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2